Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rituxan
Biotech
Candid flashes big ambitions with $370M debut
Candid’s launch combines fundraising and the acquisition of two biotechs, Vignette Bio and TRC 2004, along with their lead assets.
Darren Incorvaia
Sep 9, 2024 9:00am
FDA puts Unum T cell therapy trial on hold after adverse events
Jul 3, 2019 10:52am
Forty Seven’s anti-CD47 combo shows promise in non-Hodgkin lymphoma
Nov 1, 2018 10:28am
Cancer player Nordic Nanovector stokes takeover talk
Feb 21, 2017 6:01am
Novartis goes after Roche’s biggest earner Rituxan in Europe
May 25, 2016 6:43am
